N-Ethylpentylone (β-keto-ethylbenzodioxolylpentanamine,βk-ethyl-K,βk-EBDP,ephylone) is asubstituted cathinone andstimulant drug which was developed in the 1960s.[2][3]
It has been reported as a noveldesigner drug in several countries including the United Kingdom,[4] South Africa,[5] New Zealand,[6] the United States,[7] and Australia.[8] In 2018,N-ethylpentylone was the most common drug of the cathinone class to be identified inDrug Enforcement Administration seizures.[9]
In vivo studies in mice demonstrated that acute intraperitoneal administration of N-ethylpentylone induced anincrease in locomotor activity,anxiolytic effects but also anaggressive behaviour as well as social exploration deficits. Repeated exposure to N-ethylpentylone induced hyperthermia, anorexia and rewarding effects. During withdrawal after repeated administration, depression-like symptoms, hyperlocomotion, and a decrease of social exploration were observed.[16][17]
^GB 1085135, "Substituted phenyl-α-amino ketones", published 1969, assigned to Boehringer Sohn Ingelheim
^Wood MR, Bernal I, Lalancette RA (October 2017). "The hydrochloride hydrates of pentylone and dibutylone and the hydrochloride salt of ephylone: the structures of three novel designer cathinones".Structural Chemistry.28 (5):1369–1376.doi:10.1007/s11224-017-0951-x.ISSN1040-0400.S2CID102424824.
^Blanco G, Vidler D, Roper C, Wood DM, Dargan PI, Keating L, et al. (December 2021). "Acute toxicity from the synthetic cathinoneN-ethylpentylone (ephylone) in the United Kingdom".Clinical Toxicology.59 (12):1270–1273.doi:10.1080/15563650.2021.1909730.PMID33855924.S2CID233242607.
^Espinosa-Velasco M, Reguilón MD, Bellot M, Nadal-Gratacós N, Berzosa X, Puigseslloses P, et al. (January 2022). "Behavioural and neurochemical effects after repeated administration of N-ethylpentylone (ephylone) in mice".Journal of Neurochemistry.160 (2):218–233.doi:10.1111/jnc.15542.hdl:2445/183029.PMID34816436.S2CID244528106.
